KLRB1 and neoplasm: In addition to the PD-1 pathway, recent work has identified expression of the inhibitory receptor CD161 on intratumoral T cells in glioblastoma, and blockade of CD161 enhanced T cell anti-tumor activity both in vitro and in GL261 transplantable mouse models (74).